Homechevron_rightPortfoliochevron_rightHealthcarechevron_rightBiVACOR

BiVACOR

A Total Artificial Heart (TAH), to replace complete function of a patient’s failing heart

Visit Website
north_east
  • Sector

    Healthcare & biotech

  • lead partner

    Dr Paul Kelly

  • Deal Team

    Dr Michelle Deaker, Anne-Marie Birkill

  • 1V Board Representation

    Dr Paul Kelly, Chairman(2011-current),
    Sarah Meibusch, Alternate Director (Board Observer)
    (2020 – current), Anne-Marie Birkill,
    Board Observer (2016-2020),
    Dr Michelle Deaker, Board Observer (2011-2014)

Synopsis

Participated in Series A financing to fund the development of the external controller for the TAH (February 2018)

chevron_leftPreviosly
Prota Therapeutics
18 May 2022
Nextchevron_right
8i
18 May 2022
View All
decor decor decor
decor decor decor decor decor
clear Close
.01
chip
Investment pillar

Technology

Unlocking the full potential of tech and tech enabled scale-up companies.

EXPLORE
.02
cells
Investment pillar

Healthcare

Specialising in therapeutics, devices and diagnostics at or near clinical development, with a clear commercial, regulatory and reimbursement pathway.

EXPLORE
.03
dna
Investment pillar

Venture Credit

Venture credit (or venture debt) is a less-dilutive, low cost, complimentary form of capital to equity available to high growth technology and healthcare companies in Australia & New Zealand.

EXPLORE